

20th Street and Constitution Ave. NW, Washington, DC 20551.

FOR FURTHER INFORMATION CONTACT: Lara Lylozian, Deputy Associate Director and Chief Accountant, (202) 815-9088; Matt Walker, Manager, Insurance Supervision & Regulation, (202) 570-1473; Jennifer Abbott, Senior Insurance Policy Analyst, (240) 374-7775; Division of Supervision and Regulation; or IPAC@frb.gov. For users of TDD-TYY, please call 711 from any telephone, anywhere in the United States.

SUPPLEMENTARY INFORMATION: The Economic Growth, Regulatory Relief, and Consumer Protection Act (EGRRCPA) established at the Board an Insurance Policy Advisory Committee (IPAC) to advise the Board on international capital standards and other insurance matters. This notice advises individuals of the opportunity to be considered for appointment to the IPAC. To assist with the appointment of IPAC members, the Board considers information submitted by the candidate, public information, and any other relevant information the Board determines to consider.

Council Size and Terms

The IPAC has at most 21 members. IPAC members serve staggered three-year terms. Members are appointed to three-year terms unless the Board appoints a member to fill a vacant unexpired term. A member that is appointed to serve a three-year term begins his or her service on the first January 1 occurring after his or her appointment. A member appointed to fill a vacant unexpired term serves for the remainder of the term. The Board provides a nominal honorarium and reimburses members only for their actual travel expenses, subject to Board policy.

Statement of Interest

A Statement of Interest must contain the following information:

- Full name;
- Address;
- Phone number; and
- Email address.

At their option, candidates may provide additional information for consideration.

Qualifications

IPAC candidates should be insurance experts. The Board provides equal appointment opportunity to all persons without regard to race, color, religion, sex (including sexual orientation, gender identity, and pregnancy), national origin, age, disability, genetic information, or military service. In addition, the Board seeks, consistent

with section 211 of EGRRCPA,¹ a diverse set of expert perspectives from the various sectors of the U.S. insurance industry including life insurance, property and casualty insurance and reinsurance, agents and brokers, academics, consumer advocates, and experts on issues facing underserved insurance communities and consumers. The Board also seeks relevant actuarial, legal, regulatory, and accounting expertise, as well as expertise on lines of business underwritten by its currently supervised population of insurance institutions.

Members must be willing and able to participate in conference calls and prepare for and attend meetings in person. Membership and attendance is not delegable.

By order of the Board of Governors of the Federal Reserve System, acting through the Director of the Division of Supervision and Regulation under delegated authority.

Benjamin W. McDonough,

Deputy Secretary of the Board.

[FR Doc. 2025-15234 Filed 8-11-25; 8:45 am]

BILLING CODE 6210-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Findings of Research Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: A finding of research misconduct has been made against Ryan Evanoff (Respondent), former Scientific Assistant, Department of Veterinary Microbiology and Pathology, Washington State University. Respondent engaged in research misconduct under 42 CFR part 93 in research funded by the U.S. Public Health Service (PHS), specifically National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), grant R21 AI126304. An administrative action, specifically debarment for a period of three (3) years, was implemented and is detailed below.

FOR FURTHER INFORMATION CONTACT:

Sheila R. Garrity, JD, MPH, MBA, Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 240, Rockville, MD 20852, (240) 453-8200.

SUPPLEMENTARY INFORMATION: Notice is hereby given that the Office of Research Integrity (ORI) and the Suspension and Debarment Official (SDO) have taken final action in the following case:

Ryan Evanoff, Washington State University (WSU): Based on the preponderance of the evidence from the WSU investigation and obtained by ORI in its oversight review, ORI found that Mr. Evanoff, former Scientific Assistant, Department of Veterinary Microbiology and Pathology, WSU, engaged in research misconduct under 42 CFR part 93 in research funded by PHS, specifically NIAID, NIH, grant R21 AI126304.

ORI found by a preponderance of the evidence that Respondent intentionally and knowingly falsified and/or fabricated the following DNA sequences reported in research records, each of which purports to include data from a different sequencing reaction: pC-293_pcDNAF_CZ3082_1.seq, pC-293_pcDNAR_CZ3083_2.seq, pQ-293_pQEfPR_CZ3084_3.seq, pQ-293_pQEfPR_CZ3085_4.seq, pQ-CD81_pQEfPR_CZ3086_1.seq, and pQ-CD81_pQEfPR_CZ3087_2.seq.

Based on the information in the administrative record, the HHS SDO proposed debarment under 2 CFR 180.800(b)(1)—“Violation of the terms of a public agreement or transaction so serious as to affect the integrity of a Federal agency program, such as willful failure to perform in accordance with the terms of one or more public agreements or transactions;” and 2 CFR 180.800(d)—“Any other cause that is so serious or compelling in nature that it affects your present responsibility” to protect the Federal Government’s interest.

HHS provided Respondent the opportunity to contest the proposed debarment under 42 CFR part 93 by requesting a hearing before an administrative law judge with the HHS Departmental Appeals Board or alternatively, in lieu of requesting a hearing, to contest under 2 CFR part 180. Respondent did not contest within the prescribed 30-day period. Accordingly, the following administrative action has been implemented:

- For a period of three (3) years, beginning on June 16, 2025, Respondent is debarred from participating in “covered transactions” as defined in 42 CFR § 180.200 and procurement transactions covered under the Federal Acquisition Regulation (48 CFR chapter 1).

Dated: August 8, 2025.

Sheila R. Garrity,

Director, Office of Research Integrity, Office of the Assistant Secretary for Health.

[FR Doc. 2025-15283 Filed 8-11-25; 8:45 am]

BILLING CODE 4150-31-P

¹ 31 U.S.C. 313 note.